May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Functional and angiographic findings in patients with diabetic maculopathy treated with Selective–RPE–Laser–Treatment (SRT)
Author Affiliations & Notes
  • H.G. I. Elsner
    Dept. of Ophthalmology, UKSH Campus, Lübeck, Germany
  • E. Poerksen
    Dept. of Ophthalmology, UKSH Campus, Lübeck, Germany
  • C. Klatt
    Dept. of Ophthalmology, UKSH Campus, Kiel, Germany
  • A. Bunse
    Dept. of Ophthalmology, UKSH Campus, Kiel, Germany
  • D. Theisen–Kunde
    Med Laser Ctr, Lübeck, Germany
  • R. Brinkmann
    Med Laser Ctr, Lübeck, Germany
  • P. Hamilton
    St. Thomas Hospital, London, United Kingdom
  • R. Birngruber
    Med Laser Ctr, Lübeck, Germany
  • H. Laqua
    Dept. of Ophthalmology, UKSH Campus, Lübeck, Germany
  • J. Roider
    Dept. of Ophthalmology, UKSH Campus, Kiel, Germany
  • Footnotes
    Commercial Relationships  H.G.I. Elsner, None; E. Poerksen, None; C. Klatt, None; A. Bunse, None; D. Theisen–Kunde, None; R. Brinkmann, None; P. Hamilton, None; R. Birngruber, None; H. Laqua, None; J. Roider, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4105. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.G. I. Elsner, E. Poerksen, C. Klatt, A. Bunse, D. Theisen–Kunde, R. Brinkmann, P. Hamilton, R. Birngruber, H. Laqua, J. Roider; Functional and angiographic findings in patients with diabetic maculopathy treated with Selective–RPE–Laser–Treatment (SRT) . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4105.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:Selective–RPE–Laser–treatment (SRT) is currently investigated in a multicenter clinical trial for patients with diabetic maculopathy (DMP). In comparison to conventional Argon laser treatment, SRT uses a train of short laser pulses and selectively damages RPE cells sparing retinal structures. This clinical trial is designed to evaluate the visual and morphologic outcome of patients with focal DMP treated with SRT. Here the visual and angiographical outcome of the patients treated at the study center Lübeck is reported. Methods:20 eyes of 20 patients with focal DMP have been enrolled into the study in Lübeck after having passed a screening examination with a standardized visual acuity (VA) test using ETDRS–Charts, fundus photographs, Fluorescein angiography and optical coherence tomography (OCT). So far 17 eyes of 17 patients have been treated with SRT using a frequency doubled Q–switched Nd:YLF laser (527 nm). Each laser exposition applies a train of 30 pulses, each 1,7 µs of duration, at a repetition rate of 100 Hz. Follow–up examinations were performed after 3 und 6 months. Visual acuity and Fluorescein angiography findings were evaluated. Results:So far 9 patients have completed the 6 months follow–up. After 6 months 5 patients have gained more than 2 lines (median 2,6 lines) and the other 4 patients have stabilized within ± 1 line (median –0,6 lines). At 3 months the median change in VA is + 0,4 lines. On Fluorescein angiography we have seen a reduction of leakage activity after 6 months in 3 patients. 5 patients showed no change in terms of leakage activity. In 1 patient leakage activity has increased after 6 months. Conclusions:SRT is a safe laser treatment for focal DMP and offers the potential to stabilize and improve visual acuity and to reduce and stabilize angiographic leakage activity in patients with focal DMP. The morphologic information gained by fluorescein angiography does not explain the changes in VA in some cases.

Keywords: laser • retinal pigment epithelium • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×